由于竞争,美国减肥药价格在2026年大幅下降,Zepbound和Wegovy现在低至每月149美元299美元. U.S. weight-loss drug prices dropped sharply in 2026 due to competition, with Zepbound and Wegovy now as low as $149–$299 monthly.

2026年,激烈的竞争使美国减肥药价格大幅下降. Eli Lilly 的 Zepbound 和 Wegovy 现在每月只需 149 至 299美元,而之前的 1,000 元和 1,600 元之间已经下跌了. In 2026, intense competition has driven U.S. weight-loss drug prices down significantly, with Eli Lilly’s Zepbound and Wegovy now available for as little as $149 to $299 per month, down from over $1,000 and $1,600. 迫使像Ruth Gonzalez这样的患者付出自己的代价. This shift follows widespread insurance denials for obesity treatment, pushing patients like Ruth Gonzalez to pay out of pocket. 制药商通过网站直接向消费者销售,与沃尔玛和科斯托合作, 并对非标签竞争对手采取法律行动. Drugmakers are responding by selling directly to consumers via websites, retail partnerships with Walmart and Costco, and legal actions against off-label competitors. 这种趋势引发了关于直接向消费者推广模式是否能提高透明度,减少对药店福利管理者的依赖的争论. 支持此举的人物包括前总统特朗普通过他的TrumpRx倡议. The trend has sparked debate over whether a direct-to-consumer model can increase transparency and reduce reliance on pharmacy benefit managers, with support from figures like former President Trump through his TrumpRx initiative. 专家警告称,由于需求下降和竞争对手减少,价格下跌可能不会扩展到其他药物上.尽管近期取得了进展,但可负担性仍然是一个持续的挑战. However, experts warn the price drops may not extend to other drugs due to lower demand and fewer competitors, leaving affordability a persistent challenge despite recent gains.